In phase 3 trials, Eli Lilly’s experimental triple‐hormone therapy retatrutide delivered an average body-weight reduction of 28.7% at 68 weeks, outpacing the 26.6% achieved by its approved tirzepatide formulation under similar dosing. Notably, over 12% of trial participants with co-existing knee osteoarthritis reported complete relief from joint pain by the study’s end, suggesting retatrutide could expand Lilly’s market opportunity beyond metabolic and glycemic control into rheumatologic applications.

In the quarter ending September 30, 2025, Eli Lilly reported consolidated revenue of $17.6 billion, up 54% year-over-year. Sales of its two GLP-1 receptor agonists—Mounjaro for type 2 diabetes and Zepbound for weight management—totaled $10.1 billion and accounted for the lion’s share of that growth. Both products are growing at more than 100% annually in key U.S. and international markets, and management expects continued strong prescription volume as global obesity treatment guidelines evolve.

Trading at a price-to-earnings multiple above 50, Eli Lilly’s valuation is higher than the S&P 500 average but is supported by sustained double-digit topline growth and a deep pipeline. Investors are pricing in potential approvals for an oral GLP-1 candidate later this year and additional indications for retatrutide. With obesity treatment penetration still below 10% in most developed markets and expanding insurer coverage, analysts view the current valuation as justified given the company’s leadership in next-generation metabolic therapies.